ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Iodine I 131 IPA

Also written as “TLX-101-Tx + Lomustine” and “131I-IPA”.

Its studies are mostly in Glioblastoma, led by Telix Pharmaceuticals.

Furthest: phase 3, since Jul 17, 20252 company-led studies, 2 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Telix Pharmaceuticals22 open or runningphase 3since Jul 17, 2025Apr 22, 2022Jun 2027phase 1 · NCT05450744

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 22, 2022First study: phase 1 study in NeoplasmsFirst studyNCT05450744 · 12 enrolled · Australia, Austria, Netherlands
  2. Jul 17, 2025Phase 3 study in NeoplasmsNCT07100730 · 51 planned · Australia, Austria, Belgium and more
  3. Nov 16, 2026Primary completion moved from 2027-07 to 2028-07Date moved laterphase 3 · +12 months · NCT07100730

Ahead

  1. Jun 2027Primary completion: phase 1 study in NeoplasmsNCT05450744
  2. Jul 2028Primary completion: phase 3 study in NeoplasmsNCT07100730

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07100730Neoplasms · Australia, Austria, Belgium and more3RecruitingJul 202851
NCT05450744Neoplasms · Australia, Austria, Netherlands1Active, not recruitingJun 202712

How it is read

Names in the registry

  • “TLX-101-Tx + Lomustine”, 1 entry
  • “131I-IPA”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.